Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olvimulogene nanivacirepvec + platinum-doublet chemotherapy + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genelux
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intraperitoneal, Intravenous
01
Overview
Olvi-Vec + platinum-doublet chemotherapy + bevacizumab is an investigational combination regimen being evaluated for the treatment of platinum-resistant or refractory ovarian, fallopian tube, and primary peritoneal cancers. The regimen consists of Olvi-Vec (olvimulogene nanivacirepvec), a proprietary, modified oncolytic vaccinia virus administered intraperitoneally, followed by systemically administered platinum-doublet chemotherapy (typically carboplatin or cisplatin combined with another chemotherapeutic agent) and the anti-VEGF monoclonal antibody bevacizumab. Olvi-Vec is designed to selectively infect and destroy cancer cells, stimulate a tumor-specific immune response, and remodel the immunosuppressive tumor microenvironment, thereby potentially re-sensitizing the tumor to subsequent platinum-based chemotherapy. This combination is currently being evaluated in the Phase 3 OnPrime/GOG-3076 clinical trial sponsored by Genelux Corporation.
- Other names
- Olvi-Vec + platinum-doublet + bevacizumabOlvi-Vec + platinum-doublet chemotherapy + bevacizumabolvimulogene nanivacirepvec + platinum-doublet + bevacizumabolvimulogene nanivacirepvec + platinum-doublet chemotherapy + bevacizumab
02
Targets
DNASTAT1 (Signal transducer and activator of transcription protein 1)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on olvimulogene nanivacirepvec + platinum-doublet chemotherapy + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olvimulogene nanivacirepvec + platinum-doublet chemotherapy + bevacizumab.